Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Feb 16, 2015 - RNA Therapeutics

start date: Feb 16, 2015
Print

Event:

RNA Therapeutics


Starts:
Monday, February 16, 2015 at 10:00

Ends:
Tuesday, February 17, 2015 at 18:00

Location:
Marriott Hotel, Regents Park, 128 King Henry's Road London, United Kingdom

RNA Therapeutics 2015 returns to London on 16th and 17th February, gathering a room full of scientific pioneers and industry experts to identify the latest advancements, best practice and strategies to maximise return on investment.

The cutting edge event will ask questions such as:

What are the current opportunities, obstacles and solutions for developing effective RNAi based drugs? What makes CRISPR-Cas special and how can be used as a role model for personalised medicine? Why use a patent to protect a biotech innovation? How do we unlock the potential with locked nucleic acid? How does the next generation of ASOs demonstrate robust target knock down in multiple preclinical cancer models?  

Hear case study driven presentations from an array of market leaders such as Roche, CRISPR Therapeutics, Leiden University Medical Centre, MiNa Therapeutics and AstraZeneca, discussing the latest advancements and programmes, CRIPSPR gene editing technologies, hepatic targeting, viral delivery, the patent application process, RNA splicing, plus much more!

KEY SPEAKERS 

Claude Paul Malvy, Professor, Universite Paris Sud - CONFERENCE CHAIR 

Joerg Kaufmann, Chief Scientific Officer, Silence Therapeutics - CONFERENCE CHAIR

Bo Rode Hansen, VP, Drug Discovery & Alliance, Roche

Rodger Novak, CEO, CRISPR Therapeutics

Annemieke Aartsma-Rus, Associate Professor, Leiden University Medical Center

Nagy Habib, Chairman and Co Founder, MiNa Therapeutics

David Blakey, Chief Scientist, AstraZeneca

REASONS TO ATTEND 

Take away best practice learning on efficient and targeted efforts to maximise return on investment 

Hear key case studies from leading companies and gain the edge in confronting the challenges of oligonucleotide R&D 

Discover the latest clinical data in RNAi, ASO and miRNA medicine including the latest RNA activation approaches 

Review new conjugate/aptamer/lipid/polymer/nanoparticle delivery systems to enhance the efficacy and bioavailability of compounds 

Update on the state of CRISPR technology for therapy 

Enhance knowledge on intellectual property issues (IP)

For further information click here

Media Partners

 

Exhibitions & Events